MIV 150

Research use only, not for human use.

A high-affinity, allosteric HIV-1 and HIV-2 reverse transcriptase inhibitor (NNRTI) with EC50 of 1 nM.

A high-affinity, allosteric HIV-1 and HIV-2 reverse transcriptase inhibitor (NNRTI) with EC50 of 1 nM; possesses poor oral bioavailability, and demonstrates efficacy when formulated as a topical microbicide (PC-815: Carrageenan gel formulation).HIV Infection Phase 1 Clinical.

The activity of MIV-150 to protect target cells from infection is assayed using a syncytial assay. The EC50 of MIV-150 against HIV-1MN in CEM.SS cells is below 1 nM. These data are in agreement with the findings of Medivir. MIV-150 effectively inactivated free virus with an EC50 of 0.004 μg/mL (or 0.01 μM). It is demonstrated MIV-150 is highly effective against HIV and that the drug blocks viruses that are resistant to other marketed HIV antiretrovirals such as Nevirapine, Delavirdine, and Efavirenz. In addition, resistance to MIV-150 develops more slowly than to other anti-HIV drugs tested. For example, in vitro studies demonstrate that resistance development in the presence of nevirapine and delavirdine takes only 4 to 5 weeks compared with 45 weeks in the presence of MIV-150.

——

PC-815 | MIV150

Microbiology/Virology

HIV

HIV

Infection

HIV Infection

231957-54-3

368.4

C19H17FN4O3

>98% (HPLC)

——

O=C(N[C@@H]1[C@H](C2=C(F)C=CC(C(CC)=O)=C2O)C1)NC3=NC=C(C#N)C=C3

N-(5-Cyano-2-pyridinyl)-N'-[(1S,2S)-2-[6-fluoro-2-hydroxy-3-(1-oxopropyl)phenyl]cyclopropyl]urea

(-20℃)

With Ice Pack

≥ 2 years